Category Archives: News

Bain Capital and Stoneweg to expand Italian logistics development JV with €200 million investment

BainCapital

  • The JV’s AUM and pipeline in Italy now totals 330,000 sqm across five schemes, with a GDV of c.€500 million

LONDON – June 3, 2025 – Bain Capital, a global private investment firm, and Stoneweg, the alternative investment group specializing in Real Assets, on behalf of their Italian value add logistics Joint Venture (the “JV”), have agreed to forward purchase, from the leading Italian logistics developer VLD, a €200 million portfolio of six, grade A logistics warehouses, in three locations, totaling 225,000 sqm of GLA.

Located in established logistics hubs, the investments underscore the JV’s high conviction in a sector where muted development activity is keeping vacancy rates contained and driving attractive rental growth prospects, and a market where tenant demand is being underpinned by compelling demographic and favorable evolving consumers behaviors.

The portfolio comprises:

  • In Greater Florence, a 45,000 sqm development across two buildings, currently undergoing construction
  • In Southern Rome, a 150,000 sqm scheme across three big-box buildings, to be delivered between the end of 2026 and 2028. Occupiers will benefit from its connectivity to the A1 highway, making it convenient to serve Rome as well as Southern Italy
  • In Greater Bologna, a 33,000 sqm property, which is expected to be delivered by H1 2027. The asset benefits from immediate access to A1 highway.

All of the assets will be developed to the highest Grade-A standards and are set to achieve at least a “LEED Gold” ESG certification.

These transactions follow the JV’s initial investments in Bari and Tuscany, where the JV has recently delivered two LEED-gold certified logistics schemes totaling 110,000 sqm.

Rafael Coste Campos, a Partner at Bain Capital, said: “We maintain a positive outlook on European logistics and, across the locations where we are present, are well positioned to benefit from the current market tailwinds. We see a solid demand outlook, fostered by secular themes of e-commerce penetration and nearshoring, a reduced pipeline of modern, Grade-A product, whilst witnessing increasing quality requirements from tenants. All this is contributing to contained vacancy and growing rents. Our European Grade-A logistics portfolio has reached a critical mass of $1.5 billion GDV today, and we are looking to expand further. This investment marks a significant milestone in our strategy and further strengthens our long-term partnership with Stoneweg.”

Joaquin Castellvi, Co-Founder and Head of Strategic Investments at Stoneweg commented: “The Italian logistics sector continues to be characterized by sub-5% vacancy levels and has been a top performer in 2025, with investment activity up 121% year on year, underlining the sector’s defensive characteristics despite the uncertain global economic backdrop. Driven by demand from the renewable energy, luxury maritime and e-commerce logistics segments, and supported by Italy’s favourable GDP and employment outlook, we anticipate strong occupier demand for these highly sustainable assets. Alongside Bain Capital, and leveraging the strength of our local teams, as well as the opportunities being presented by current market dislocation, we have the ambition and near-term pipeline to significantly scale the platform.”

Stoneweg and Bain Capital were advised by DILS and Colliers (commercial), Linklaters (legal, tax, structuring and regulatory counsel and CBRE (technical due diligence).
About Bain Capital
Founded in 1984, Bain Capital is one of the world’s leading private investment firms. We are committed to creating lasting impact for our investors, teams, businesses, and the communities in which we live. As a private partnership, we lead with conviction and a culture of collaboration, advantages that enable us to innovate investment approaches, unlock opportunities, and create exceptional outcomes. Our global platform invests across five focus areas: Private Equity, Growth & Venture, Capital Solutions, Credit & Capital Markets, and Real Assets. In these focus areas, we bring deep sector expertise and wide-ranging capabilities. We have 24 offices on four continents, more than 1,850 employees, and approximately $185 billion in assets under management. To learn more, visit www.baincapital.com.

About Stoneweg
Stoneweg is a global alternative investment group, specialized in Real Assets, headquartered in Geneva Switzerland, and part of SWI Group.

Stoneweg was founded in 2015 by a veteran team of investment professionals and has grown its platform and capabilities both organically through joint ventures and through strategic acquisitions to ca. €9.0 billion of Asset Under Management(“AUM”).

It is a trusted capital partner and investment manager to a range of global and local investors, capital providers and banking partners and has a strong track record of investing and creating value in a variety of structures, including club deals, joint ventures and co-investments.

The group relies on local operating teams to identify, develop and manage real assets and other alternative investments around the world. With more than 350 employees, Stoneweg has operational presence and teams on the ground in 23 offices across 17 countries in Europe, the US and Singapore. For more information, visit www.stoneweg.com.

Media Contacts

Europe

Jason Lobo

 Camarco

Categories: News

Tags:

Ardian and Rockfield grow pan-European Student Accommodation strategy with further €300 million commitment from CBRE Investment Management

Ardian

Ardian, a world-leading private investment firm, and Rockfield, a vertically integrated living platform, are further strengthening their Purpose-Built Student Accommodation (PBSA) strategy with a new €300 million commitment from CBRE Investment Management on behalf of its Indirect Private Real Estate Division.

CBRE Investment Management (CBRE IM), a leading global real assets investment management firm, acted as a founding investor in Ardian and Rockfield’s PBSA strategy when it launched in October last year. This early follow-on commitment brings CBRE IM total commitment to the strategy to €800 million.

Ardian and Rockfield aim to build a diversified portfolio of high-quality, purpose-built student accommodation assets across leading university cities in continental Europe, targeting markets with demand imbalances from rising student populations and structural undersupply, specifically in Italy, the Netherlands, Spain, Portugal, Germany and France.

The strategy has achieved strong momentum in its first months, with five acquisitions completed to date, establishing a diversified and growing seed portfolio of over 3,000 beds across Europe. This includes a fully let residence in Florence, a newly built 500-bed asset in central Bologna, a LEED Platinum-certified scheme in Barcelona, the Minervahaven development in Amsterdam recognised as Europe’s most sustainable PBSA asset, and a mixed-tenure property in Milan offering both market and subsidised student housing.

Nearly 100% of the initial €500 million equity commitment has been deployed, with four further acquisitions in France, Spain and the Netherlands set to be completed in the coming months. This will bring the platform to a total of 5,000 beds.

This early success demonstrates the strength of the strategy’s disciplined investment criteria, and its ability to move with speed and precision.

With €800 million of equity now committed to the strategy, representing nearly €1.3 billion in investment capacity, and a growing pipeline across the continent, its next phase will focus on expanding footprint in key markets, including currently untapped markets such as Germany.

The strategy has aCore+ profile with a focus on income-producing assets in supply-constrained cities, supporting the delivery of new, best-in-class student residences.

“To have fully committed our seed capital so quickly, and to see CBRE IM increasing their exposure ahead of schedule, sends a very clear signal. It confirms that our thesis, timing and activity are strongly aligned with investor and market needs. We launched this strategy to solve a structural gap in Europe’s urban living needs, and this momentum shows that we’re delivering”. Matteo Minardi, Head of Real Estate Italy and Managing Director, Ardian

“We take immense pride in the platform we set out to build with Ardian, being able to deploy capital quickly without compromising on quality. Our in-house investment, development, operations and asset management model means is strategically designed to source, execute and deliver at scale in a way that reflects the social and environmental standards institutions and end customers increasingly expect. CBRE IM’s renewed commitment is a strong endorsement of the model we’ve built and the opportunity ahead. We are grateful for the renewed trust the current and incoming investors are placing in us.” Juan Manuel Acosta, CIO, Rockfield Real Estate

”The student housing market in Continental Europe remains a compelling and resilient growth opportunity. We are pleased to see our capital being strategically deployed to curate a high-quality portfolio of student assets in undersupplied European cities characterized by strong demand. This additional commitment underscores our long-term conviction in this asset class and reinforces our thematic investment approach.” Line Verroken, Head of Living Investments, EMEA, CBRE IM Indirect Private Real Estate

Sustainability is embedded into the platform’s approach. All assets are targeting or have achieved leading ESG certifications such as BREEAM and LEED, and seek alignment with the objectives of the Paris Agreement. Across the portfolio, design and refurbishment strategies integrate climate risk assessment, renewable energy procurement and wellbeing-focused living environments. The platform also actively monitors socioeconomic impact, including affordability and accessibility, reinforcing its commitment to responsible urban development.

ABOUT ARDIAN

Ardian is a world-leading private investment firm, managing or advising $180bn of assets on behalf of more than 1,850 clients globally. Our broad expertise, spanning Private Equity, Real Assets and Credit, enables us to offer a wide range of investment opportunities and respond flexibly to our clients’ differing needs. Through Ardian Customized Solutions we create bespoke portfolios that allow institutional clients to specify the precise mix of assets they require and to gain access to funds managed by leading third-party sponsors. Private Wealth Solutions offers dedicated services and access solutions for private banks, family offices and private institutional investors worldwide. Ardian’s main shareholding group is its employees and we place great emphasis on developing its people and fostering a collaborative culture based on collective intelligence. Our 1,050+ employees, spread across 19 offices in Europe, the Americas, Asia and Middle East are strongly committed to the principles of Responsible Investment and are determined to make finance a force for good in society. Our goal is to deliver excellent investment performance combined with high ethical standards and social responsibility.
At Ardian we invest all of ourselves in building companies that last.

ardian.com

ABOUT ROCKFIELD REAL ESTATE

Rockfield was established in 2014 with a clear mission to create high quality and sustainable housing solutions for students, young professionals and families in urban areas. Our founders recognized the growing demand for affordable housing in major cities, coupled with an increasing need for innovative living concepts that not only provide a place to live but also enable residents to grow and thrive within a community.
With this vision in mind, Rockfield started a journey to build a fully integrated real estate company. From the start, we chose to keep all aspects of real estate management in-house, from project development and acquisition to investment and property management. This approach has allowed us to offer tailored solutions that meet needs of both investors and tenants.
Since our inception, we have experienced impressive growth and evolved into a leading investment manager with a portfolio of over €2 billion in assets under management and around 8,000 housing units across various European cities.

rockfield.nl

Media Contacts

ARDIAN

HEADLAND

ardian@headlandconsultancy.com

ROCKFIELD REAL ESTATE

Sander van Essen

Sander.van.essen@rockfield.nl

Categories: News

Tags:

Regional Rail continues its expansion in the Midwest with the acquisition of the Minnesota Commercial Railway

3I

3i-backed Regional Rail, a leading owner and operator of short-line freight railroads across North America, has acquired the Minnesota Commercial Railway (“MNNR” or the “Company”). MNNR is an 86-mile railroad serving the Twin Cities area in Minnesota, with direct connection to four Class I rail networks, in addition to the Twin Cities & Western Railroad. The railroad provides freight-hauling, storage, and transload services to a diverse set of customers across a variety of end-markets, including metals, fuel & oil, chemicals & plastics, food & agriculture, and lumber. The Company also owns and operates Commercial Transload of Minnesota (“CTM”), which provides warehousing, transloading, and trucking services to local manufacturers in the region. The acquisition further expands Regional Rail’s North American network, which now includes 17 railroads across 9 U.S. states and 2 Canadian provinces.

Al Sauer, President and CEO, Regional Rail, commented:

“We are honored that Becky Gohmann has entrusted Regional Rail to continue the legacy established by the late John Gohmann at the Minnesota Commercial, and we are excited to partner with the team at the MNNR and CTM to expand these operations and strengthen the business for the future. We look forward to building on the Company’s track record of high-quality service and providing the team with the expanded resources of our broader platform to drive additional growth.”

Rob Collins, Managing Partner and Head of North American Infrastructure, 3i, commented:

“Minnesota Commercial is a great fit for Regional Rail’s strategy of partnering with strong local operators, while preserving the legacy and history of its founder. We look forward to providing continued support to Regional Rail for all future opportunities.”

Rebecca Gohmann, Owner of the Minnesota Commercial Railway:

“I am very proud of John’s leadership and dedication to the Minnesota Commercial Railway, as well as the dedication and hard work of our employees. I believe Regional Rail is a great fit to continue the legacy my husband started in 1987 of supporting our employees, our customers, and new growth opportunities.”

Since partnering in July 2019, 3i and Regional Rail have grown from three railroads in the Northeast to seventeen freight-railroad operations located across North America. The company provides freight transportation, car-storage, and transloading services across the United States and western Canada. In addition to freight services, Regional Rail provides railroad-crossing signal design, construction, inspection, and maintenance services to a diverse base of short-line and industrial customers in 21 U.S. states via the company’s Diamondback Signal subsidiary.

-Ends-

Download this press release 

For further information, contact:

Silvia Santoro
Investor enquiriesKathryn van der Kroft
Media enquiries		 Tel: +44 20 7975 3258
Email: silvia.santoro@3i.comTel: +44 20 7975 3021
Email: kathryn.vanderkroft@3i.com

Categories: News

Tags:

Carlyle partners with Rabo Investments to invest in SurePay

Carlyle

Utrecht, Netherlands and London, UK – 3 June 2025 – Carlyle Europe Technology Partners (“CETP”), in partnership with Rabobank’s investment arm Rabo Investments, today announced a strategic growth investment in SurePay, a European leader in payment verification software.

Founded within Rabobank in 2016 and headquartered in the Netherlands, SurePay is a leading provider of payment verification technology solutions to financial institutions and corporates across Europe and the UK. The company reduces fraudulent and misdirected payments through its trusted real-time IBAN-name check, Confirmation-of-Payee (CoP), Verification-of-Payee (VOP), and Fraud Risk Indicator (FRI) products, supporting 200+ banks and 750+ corporate customers. Once implemented, SurePay reduces impersonation scams by 81% and erroneous payments by 67% on average. To date, SurePay has processed more than 10 billion payment checks, playing a critical role in helping clients improve payment accuracy, prevent fraud, address continuously evolving regulatory and compliance demands, and optimise operational efficiencies.

With the backing of Carlyle and Rabo Investments, SurePay plans to further expand its suite of payment verification and fraud prevention solutions and broaden its geographic presence across Europe and beyond, with a continued focus on delivering highly reliable services to its blue-chip customers.

David-Jan Janse, CEO and co-founder of SurePay, said:
“We are thrilled to welcome Carlyle as a strategic partner for the next stage of our journey. The team is grateful to Connected Capital and Iris Capital for their partnership since 2021, and the valuable experience they have brought in scaling B2B SaaS businesses and supporting breakout technology ventures like ours. With Carlyle’s deep experience in financial infrastructure and enterprise software, they are the ideal partner to join Rabobank in supporting our ambition to strengthen our leadership across Europe and the UK, and expand into other international markets. This investment is a major milestone for our team and a strong validation of the platform we have built together with top-tier financial institutions and leading corporates around the world.”

Constantin Boye, who leads the European growth equity efforts within the CETP investment advisory team at Carlyle, said:
“SurePay is a mission-critical payment verification solutions provider with a powerful combination of proven technology and deep relationships across the European and UK banking ecosystem. The team has done an exceptional job building a platform that delivers real, measurable impact in reducing fraud and improving payment accuracy for both financial institutions and corporates. We are excited to partner with Rabo Investments in supporting SurePay as they continue to scale internationally and drive innovation in this increasingly important space.”

Carlyle is investing through its CETP V fund, a €3.2 billion vehicle focused on growth-stage technology businesses across Europe. The CETP team has extensive experience in scaling European financial technology and Governance, Risk and Compliance (GRC) software platforms, with notable investments including FRS Global, ITRS, Calastone, VWD, and Trema.

Floris Onvlee, Director at Rabo Investments, added:
“Since its founding within Rabobank, SurePay has been developed to meet the highest possible financial services quality standards with best-in-class platform reliability, scalability, and security. We believe that this bank-grade heritage, which underpins the many strengths of SurePay’s current offering, has enabled the team to execute with focus, ambition, and credibility to become a European leader in payment verification. Today, their solutions are used by many of the world’s largest financial institutions and corporates, delivering meaningful impact at enterprise scale. After a fruitful partnership with Connected Capital and Iris Capital, we are proud to continue on this growth journey with the SurePay team alongside Carlyle, supporting Rabobank’s corporate venture strategy to build a stronger and more secure financial ecosystem.”

 

About SurePay
SurePay is a leading provider of payment verification technology, headquartered in the Netherlands. The company originally pioneered the IBAN-name check solution in the Dutch market in 2017 and has since expanded across Europe and the UK with its real-time Verification-Of-Payee (VOP), Confirmation-of-Payee (CoP) and Fraud Risk Indicator (FRI) solutions. SurePay serves more than 200 banks and 750 corporate customers and has processed more than 10 billion payment checks to date, playing a critical role in helping clients prevent fraud, improve payment accuracy, and meet continuously evolving compliance and regulatory demands.

 

Media Contacts
Carlyle

Nicholas Brown
nicholas.brown@carlyle.com
+44 7471037002

 

SurePay

Ramon Verweij
ramon@surepay.eu
+31 623833068

 

Rabo Investments

Hugo Nutbey
hugo.nutbey@rabobank.nl
+31 887263463

Categories: News

Tags:

CareLineLive Secures Majority Investment from Technology Investment Firm Accel-KKR

AKKR Logo

London, UK & Menlo Park, CA – June 3, 2025 — CareLineLive, an all-in-one home care management software company, has secured a majority investment from technology-focused investment firm Accel-KKR, to spur accelerated growth, expansion and product development.

Founded in 2014 by entrepreneur Josh Hough, CareLineLive provides an all-in-one cloud-based platform for homecare agencies, integrating staff scheduling, client visits, patient records and invoicing. The company currently supports hundreds of care providers across seven countries.

Across many parts of the world, the home healthcare market continues to grow. For example, the UK’s home and domiciliary care market is worth £11.5 billion, according to insurance broker PolicyBee. The Australian home healthcare market is projected to reach USD 25.7 billion by 2030, whereas the U.S. home care providers market is valued at approximately $153.7 billion in 2025.

Hough said the investment would help accelerate the company’s growth and international reach. “Our vision has always been to make homecare better for everyone through the use of technology – for providers, carers and clients,” he said.

“This investment helps bring that future closer. Accel-KKR’s long track record of helping software companies grow is what I am most excited about. Their experience and resources will help us to grow our team, enhance our product, and deliver even more value to our customers.”

A portion of the funding will be used to establish a customer support presence in Australia, enabling round-the-clock service. “As our UK team finishes for the day, the Australia team will begin – meaning we’ll be able to support customers at any time of day,” Hough added.

The full transaction value has not been disclosed, but the investment also facilitates an exit for early backers Oakglen and Haatch. Hough also paid tribute to the outgoing investors: “We’re incredibly proud of the progress we’ve made over the last decade and I’d very much like to thank both Oakglen and Haatch for their support. This marks an exciting new chapter with Accel-KKR.”

Accel-KKR, which specialises in investing in enterprise software and tech-enabled businesses, cited CareLineLive’s technology and customer-centric ethos as among the key drivers behind its decision to invest in CareLineLive.

Maurice Hernandez, Managing Director at Accel-KKR, said, “No matter where they serve, home care providers want to focus on delivering responsive, respectful and personalized care. Technology can help carers and agencies improve efficiencies, maintain compliance and grow while being focused on their clients’ wellbeing. We’re excited to back CareLineLive and help Josh and his team continue to build market-leading solutions in this category.”

Hough said he and the senior management team will be remaining with the company for the foreseeable future.  “There’s a long-term plan in place, but it’s very much business as usual,” Hough added.

About CareLineLive
Founded in 2014, CareLineLive provides an all-in-one cloud-based platform for homecare agencies, integrating staff scheduling, client visits, patient records and invoicing. The company currently supports hundreds of care providers across seven countries. CareLineLive is one of the few companies to meet the NHS requirements to be on the approved supplier list for Digital Social Care Records. It also integrates with GP Connect, enabling access to GP records.

About Accel-KKR
Accel-KKR is a technology-focused investment firm with $21 billion in cumulative capital commitments. The firm focuses on software and tech-enabled businesses, well-positioned for top-line and bottom-line growth. At the core of Accel-KKR’s investment strategy is a commitment to developing strong partnerships with the management teams of its partner companies and a focus on building value alongside management by leveraging the significant resources available through the Accel-KKR network. Accel-KKR focuses on middle-market companies and provides a broad range of capital solutions, including buyout capital, minority-growth investments, and credit alternatives. Accel-KKR also invests across various transaction types, including private company recapitalizations, divisional carve-outs and going-private transactions. Accel-KKR’s headquarters is in Menlo Park, with offices in Atlanta, Chicago, London, and Mexico City. For more, visit accel-kkr.com.

Categories: News

Tags:

Gilde Healthcare participates in $75 Million Series D round of SpyGlass Pharma to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

GIlde Healthcare
Aliso Viejo, CA (United States)

SpyGlass Pharma, a privately-held ophthalmic biotechnology company, announced the closing of a $75 million Series D financing round. SpyGlass’ Drug Delivery Platform aims to provide multiple years of medical therapy, addressing the need for long-term management of glaucoma and other chronic ophthalmic diseases.

Gilde Healthcare joined the Series D as a new investor alongside Sands Capital and existing investors: New Enterprise Associates (NEA), RA Capital, Vensana Capital, Samsara BioCapital and Vertex Ventures HC. The funding will support the advancement of SpyGlass Pharma’s cutting-edge Drug Delivery Platform through the readout of two registrational Phase III trials, set to begin later this year.

“We appreciate the strong support from our new and existing investors, underscoring their confidence in our innovative Drug Delivery Platform,” said Patrick Mooney, CEO of SpyGlass Pharma. “We are excited to advance our platform through pivotal Phase III trials as we accelerate our commitment to addressing significant unmet needs for ophthalmic patients.

“We believe our approach represents a paradigm shift in the treatment of eye diseases, such as glaucoma, with significant advantages compared to currently commercialized therapies,” said Dr. Malik Y. Kahook, MD, Co-Founder and President of SpyGlass Pharma. “The long-term safety and efficacy demonstrated from both the first-in-human feasibility trial and the Phase II, multi-center, randomized clinical trial showing significant and sustained intraocular pressure-lowering in glaucoma patients, is compelling.”

About SpyGlass Pharma
The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver 3 years of bimatoprost to targeted tissues. Patients in the first-in-human study will continue to be followed over time, and the Company plans to share 24 month follow up data at the American Academy of Ophthalmology meeting later this year. SpyGlass completed enrollment in a Phase I/II study in the United States to investigate the safety and efficacy of its platform in a larger patient pool. SpyGlass looks forward to working closely with the U.S. Food and Drug Administration (FDA) to advance the program through Phase III clinical trials and ultimately to commercial approval. SpyGlass operates from its facilities in California and can be found online at www.spyglasspharma.com.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Categories: News

Tags:

Antares Closes $1.2 Billion Private Credit Continuation Vehicle Led by Ares Management

Antares
CHICAGO & NEW YORK–(BUSINESS WIRE)– Antares Capital and Ares Management Corporation (“Ares”) (NYSE: ARES) today announced the closing of Antares’ first continuation vehicle with over $1.2 billion in commitments. The transaction was led by Ares Credit Secondaries funds, along with a commitment from Antares.

The continuation vehicle was established to purchase assets and limited partner interests from two comingled private credit funds comprising over 100 underlying first lien, floating rate loans originated and managed by Antares. The vehicle provided existing investors with an attractive liquidity option while offering new investors exposure to quality Antares-originated private credit assets.

“This transaction underscores our strong, long-standing partnership with Ares and our shared commitment to providing quality private credit opportunities,” said Vivek Mathew, president of Antares Capital Advisers. “It also marks an important step in expanding the Antares platform and delivering new liquidity solutions to our investors.”

“We are pleased to welcome Ares as a lead investor and believe the successful close of our first continuation vehicle in today’s dynamic market highlights the quality of the Antares portfolio and the power of our origination and underwriting capabilities,” said Ben Chapin, Head of Liquidity Solutions at Antares Capital. “We are committed to structuring differentiated liquidity options tailored to both LPs and GPs, leveraging our extensive private credit experience, deep relationships and focus on credit discipline.”

“Building upon our multidecade relationship with Antares, we are proud to lead this transaction, which represents Ares’ largest credit secondary investment to date,” said Dave Schwartz, Head of Credit Secondaries, Ares. “This investment underscores our team’s differentiated experience in private credit and secondaries and our ability to deploy scaled capital. We look forward to leveraging our global relationships with leading private credit managers to deliver creative liquidity solutions that meet the needs of investors.”

Evercore served as exclusive financial advisor on the transaction.

About Antares Capital
Founded in 1996, Antares has been a leader in private credit for nearly three decades. Today with approximately $80 billion* of capital under management and administration as of December 31, 2024, Antares is an experienced and cycle-tested alternative credit manager. With one of the most seasoned teams in the industry, Antares is focused on delivering attractive risk-adjusted returns for investors and creating long term value for all of its partners. The firm maintains offices in Atlanta, Chicago, Los Angeles, New York, Toronto and London. Visit Antares at www.antares.com or follow the company on LinkedIn at https://www.linkedin.com/company/antares-capital-lp.

Antares Capital is a subsidiary of Antares Holdings LP, (collectively, “Antares”). Antares Capital London Limited is an appointed representative of Langham Hall Fund Management LLP, an entity which is authorized and regulated by the Financial Conduct Authority of the UK.

*As of December 31, 2024, all figures are estimates and subject to change upon finalization.

About Ares Management Corporation
Ares Management Corporation (NYSE: ARES) is a leading global alternative investment manager offering clients complementary primary and secondary investment solutions across the credit, real estate, private equity and infrastructure asset classes. We seek to provide flexible capital to support businesses and create value for our stakeholders and within our communities. By collaborating across our investment groups, we aim to generate consistent and attractive investment returns throughout market cycles. As of March 31, 2025, Ares Management Corporation’s global platform had approximately $546 billion of assets under management, with operations across North America, South America, Europe, Asia Pacific and the Middle East. For more information, please visit www.aresmgmt.com.

Antares
Allison Perkins
allison.perkins@antares.com

Ares
Jacob Silber | Lauren Sullivan
media@aresmgmt.com

Source: Antares Capital

Back to Media

Categories: News

Tags:

KKR Provides $600 Million Financing to Indian Conglomerate Manipal Group

KKR

Transaction marks KKR’s latest and largest credit investment in India

MUMBAI, India–(BUSINESS WIRE)– KKR, a leading global investment firm, and Manipal Education and Medical Group (“MEMG” or “Manipal Group”), a major diversified conglomerate in India, today announced a $600-million financing arranged by KKR Capital Markets and anchored by KKR’s private credit and insurance platforms to the Manipal Group. The investment will enable the Manipal Group to accelerate its corporate expansion and growth objectives by providing flexible, structured capital matched to its long-term strategic needs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250601919977/en/

The Manipal Group is a leading conglomerate in India with various institutions and major businesses across the healthcare, education, and health insurance sectors, including Manipal Health Enterprises, one of India’s top multispecialty hospitals chains in India.

KKR’s Asia Pacific Credit platform seeks to provide, among other private credit strategies, bespoke solutions to high-quality companies, entrepreneurs, promoters and sponsors that harness the strength of KKR’s private markets investment capabilities and its expertise as one of the largest alternative credit managers globally.

Gaurav Trehan, Co-Head of KKR Asia Pacific and Head of Asia Private Equity, KKR said, “We are pleased to deepen our relationship with the Manipal Group and Dr Ranjan Pai, who have established one of India’s pre-eminent and homegrown businesses, as they continue to deliver on their long-term vision. The Manipal Group has built a strong reputation over the decades as one of India’s healthcare and education leaders, and we look forward to supporting and contributing to their continued success.”

Dr. Ranjan Pai, Chairman of Manipal Education and Medical Group, said, “We are proud to welcome KKR as a strategic partner as we continue to build on Manipal’s legacy in healthcare and education. KKR’s longstanding India focus and flexible capital approach, as well as alignment with our long-term vision, present a strong fit for us.”

Diane Raposio, Partner and Head of Asia Credit and Markets at KKR, added, “This transaction underscores the strength of our global credit platform and our ability to provide strategic, scaled capital solutions to leading businesses. India is a priority market for our credit strategy, and we look to build on this momentum to be a partner of choice to more high-quality companies like Manipal on their growth ambitions.”

KKR is making its investment from its Asia Pacific Credit strategy and insurance platform. Since 2019, KKR has committed more than $8 billion across around 60 credit investments under its Asia Pacific Credit strategy, accounting for a total transaction volume of more than $21 billion.

Additional details of the transaction are not disclosed.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

About Manipal Education and Medical Group (MEMG)

Founded in 1953 by Padma Shri Dr TMA Pai, MEMG has evolved into a diversified conglomerate, with a strong presence in healthcare, education and health insurance in India and globally. MEMG’s operations touch the lives of over 20 million people annually with Manipal Hospitals scaling up to become the largest tertiary network in India. MEMG’s flagship University, Manipal Academy of Higher Education has been recognized as an Institute of Eminence by the Government of India. Claypond Capital, the family office of Dr. Pai and the investing arm of MEMG has been one of the more prolific investing family offices in India in the last 18 months. Their marquee investments include Aakash, BPL Medical, BlueStone, Easy Home Finance, First Cry, Finnable, InCred Finance, NSE, Panacea Medical, PharmEasy, Purpple, Recykal, SSI Innovations and Zepto.

Media Contacts

For KKR Asia Pacific
Wei Jun Ong
+65 6922 5813
WeiJun.Ong@kkr.com

For Manipal Group
Shyam Powar
+91 98804 75000
Shyam.Powar@claypondcapital.com

Source: KKR

 

Download PDF

Categories: News

Tags:

EQT Real Estate acquires a five-building logistics portfolio across three locations in Southern France

Picture

  • Acquisition of five logistics assets totaling approximately 148,000 square meters
  • Let to nine tenants, this highly reversionary portfolio has a weighted average remaining lease term to break of less than two years
  • With this transaction, EQT Real Estate will meaningfully increase its exposure to the core Southeast and Southwest France logistics markets

EQT Real Estate is pleased to announce that EQT Exeter Logistics Value Fund IV has acquired a best-in-class logistics portfolio of five warehouses.

The portfolio of big-box assets totals approximately 148,000 square meters and are located in the key Southern France submarkets of Avignon and Toulouse. The warehouses’ respective locations offer proximate access to core population centres via key motorways, including the A20 and the A7 which provide connectivity to Marseille and Lyon.

The properties feature Grade A technical specifications, including eaves heights averaging over ten meters, as well as ample loading and maneuvering features. The portfolio benefits from a strong, global diversified tenant base and is well-suited to meet the growing needs of today’s modern logistics users.

This acquisition strengthens EQT Real Estate’s exposure to core Southern France submarkets, which are structurally undersupplied and continue to experience resilient demand. These are highly desirable occupier markets benefiting from the excellent connectivity which supports supply chains along the Atlantic and Mediterranean coasts.

John Toukatly, Partner, Chief Investment Officer, European Logistics at EQT Real Estate, said: “We are excited to add these top-tier logistics properties to our portfolio. Situated in supply-constrained markets, these assets are highly attractive to a wide range of major big-box tenants and are well aligned with EQT Real Estate’s strategy of acquiring modern, high-potential logistics properties in underserved areas across Europe. With our operational and asset management capabilities, we intend to further enhance the value of this high-quality portfolio.”

EQT Real Estate was advised by PwC (financial and tax), Gide and GMH Notaires (legal and notarial), CBRE (commercial), Tauw (environmental), AMF (ICPE and PM) and Gleeds (technical and ESG).

Contact
EQT Press Office, press@eqtpartners.com

Downloads

About EQT Real Estate
EQT is a purpose-driven global investment organization with EUR 273 billion in total assets under management (EUR 142 billion in fee-generating assets under management) as of 31 March 2025, divided into two business segments: Private Capital and Real Assets. EQT supports its global portfolio companies and assets in achieving sustainable growth, operational excellence, and market leadership. Within EQT’s Real Assets segment, EQT Real Estate acquires, develops, leases, and manages logistics and residential properties in the Americas, Europe, and Asia. EQT Real Estate owns and operates over 2,500 properties and 540 million square feet, with over 440 experienced professionals across 50 locations globally.

More info: www.eqtgroup.com
Follow EQT Real Estate on LinkedIn

Categories: News

Tags:

bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital

Carlyle

New management, led by David Meek, is committed to rapidly scaling access to lifechanging gene therapies

Significant capital commitment from Carlyle and SK Capital will enable bluebird to grow and accelerate patient access

bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers

SOMERVILLE, Mass. — June 2, 2025 — bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”). With the closing of the transaction, bluebird’s common stock has ceased trading and will no longer be publicly listed. Carlyle and SK Capital have provided significant primary capital to support and scale bluebird’s commercial delivery of gene therapies for patients with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy.

David Meek, who became Chief Executive Officer of bluebird at close, said, “Today marks the beginning of a new era for bluebird as its go-forward financial backing and leadership team will better enable all stakeholders to realize the full potential of our revolutionary therapies. Historically, bluebird has excelled as a scientific innovator and should be very proud of the many achievements it has delivered to patients. Our vision is to further that legacy of scientific excellence while improving the commercial execution of our approved products to rapidly expand access to lifechanging gene therapies.”

“We are excited to back bluebird in partnership with SK Capital. We believe providing bluebird the necessary funding along with the new leadership team will help bluebird realize its full potential,” said Joe Bress, Carlyle Partner and Global Co-Head of Healthcare. Bali Muralidhar, Co-Managing Partner and Chief Investment Officer & COO of Abingworth, Carlyle’s life sciences investment franchise, added, “There is an incredible opportunity to bring bluebird’s groundbreaking therapies to more patients in need, and we look forward to advancing bluebird in its mission.”

“SK Capital looks forward to partnering with David and his team as well as Carlyle to scale bluebird’s pioneering gene therapies that can make a lifechanging difference for patients around the world,” said Aaron Davenport, Managing Director at SK Capital, adding, “We believe our deep collective experience in manufacturing and commercializing therapies can help drive the next chapter of bluebird’s growth.”

Incoming Team Bolsters Commercial Gene Therapy Experience 

The company’s momentum is reinforced by a deeply experienced management team, led by CEO David Meek. David brings more than 30 years of leadership in life sciences, including as CEO of Mirati Therapeutics and Ipsen. David is joined by Tom Klima as Chief Commercial & Operating Officer, Debasish Roychowdhury, M.D., as Chief Medical Officer, Wendy DiCicco as Chief Financial Officer, and Ellen Forest as Chief People Officer. Additional details are available at https://www.bluebirdbio.com/about-us/leadership.

From Scientific Breakthroughs to Delivery at Scale

With the transaction now closed, bluebird is prioritizing expanding its manufacturing infrastructure, streamlining the patient journey, supporting treatment centers, and strengthening its payer partnerships. The acquisition provides the strategic and financial backing needed to meet rising demand and drive commercial and operational excellence across the organization.

“bluebird has demonstrated what’s possible through effective gene therapy,” David added. “Now we will build the ecosystem to ensure every patient who needs these therapies can access them.”

About bluebird bio

bluebird bio is a commercial-stage biotherapeutics company focused on developing and delivering gene therapies for severe genetic diseases. With more than a decade of scientific leadership in gene therapy and three FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, the company is committed to ensuring access, reliability, and patient-centered care. bluebird is headquartered in Somerville, Massachusetts.

About Carlyle

Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and conducts its operations through three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $453 billion of assets under management as of March 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,300 people in 29 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

About SK Capital

SK Capital is a transformational private investment firm with a disciplined focus on the life sciences, specialty materials, and ingredients sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital currently has approximately $10 billion in assets under management as of December 31, 2024. For more information, please visit www.skcapitalpartners.com.

Forward Looking Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about bluebird’s future goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond bluebird’s control and could cause bluebird’s future goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect bluebird bio’s business, particularly those identified in the risk factors discussion in bluebird bio’s Annual Report on Form 10-K for the year ended December 31, 2024, as updated by its subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. These risks and uncertainties include, but are not limited to: the risk that the efficacy and safety results from bluebird’s prior and ongoing clinical trials will not continue or be seen in the commercial context; the risk that there is not sufficient patient demand or payer reimbursement to support continued commercialization of bluebird’s products; the risk of insertional oncogenic or other safety events associated with lentiviral vector, drug product, or myeloablation, including the risk of hematologic malignancy; and the risk that bluebird’s products will not be successfully commercialized. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, bluebird bio undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

Contacts: 

 

Bluebird

Courtney O’Leary 

+1 (978) 621-7347

coleary@bluebirdbio.com

 

Carlyle

Brittany Berliner
+1 (212) 813-4839
brittany.berliner@carlyle.com

 

SK Capital

Ben Dillon

+1 (646) 278-1353 
bdillon@skcapitalpartners.com

Categories: News

Tags: